MiniMed Reports Strong Q4 Sales & Positive FY27 Outlook Amid Widening Losses
Summary
MiniMed Group announced strong Q4 and full-year 2026 sales growth and a positive FY27 revenue outlook, alongside widening net losses, as it continues to launch new diabetes technology products.
Key Events
-
Strong Revenue Growth Reported
MiniMed reported Q4 net sales of $837 million, up 15.6% year-over-year (8.7% organic), contributing to record annual net sales of $3.102 billion, up 14.2% (8.0% organic).
-
Widening Net Losses
The company's net loss increased to $(183) million in Q4 FY26 from $(168) million in Q4 FY25, and to $(315) million for the full fiscal year 2026 from $(198) million in FY25.
-
Positive FY27 Organic Revenue Outlook
MiniMed expects approximately 10% organic revenue growth and an Adjusted EBITDA margin of approximately 16% for fiscal year 2027.
-
Product Pipeline Advancements & Partnership
The company announced FDA clearance for MiniMed Flex™, CE Mark for Instinct, global launch of MiniMed Go™ Smart MDI, and an extended partnership with Abbott for dual glucose-ketone sensors.
Analysis
MiniMed Group's latest earnings report highlights robust revenue growth for both the fourth quarter and full fiscal year 2026, driven by strong international performance and new product introductions. The company also provided an optimistic organic revenue growth forecast for fiscal year 2027, indicating continued market expansion. However, these gains were accompanied by a notable increase in net losses, which investors will weigh against the company's growth trajectory and product pipeline advancements, including new FDA clearances and strategic partnerships.
At the time of this filing, MMED was trading at $11.89 on NASDAQ in the Industrial Applications And Services sector. The 52-week trading range was $10.65 to $19.05. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.